Leading pharma manufacturers to expand their stocks before Brexit

06 August 2018

GMP News

Sanofi and Novartis mentioned they deliberate to extend stockpiles of medicines Britain in preparation for potential disruption if the UK crashes out of the European Union and not using a deal.

Roche, the world’s largest maker of most cancer medicines, additionally mentioned it was taking “appropriate action” to overview its stock ranges in an effort to shield provides to sufferers.

Britain’s largest drugmaker, GlaxoSmithKline, mentioned it was taking steps to safe the availability of its medicines and vaccines forward of the UK’s departure from the EU, with out going into particulars.

Supplies of 1000’s of medicines are liable to disruption if Britain leaves the EU and not using a deal, forcing producers to arrange duplicate product testing and licensing preparations to make sure their medicine keep on the market.

Leading drugmakers have lengthy been vocal of their considerations about Brexit and the necessity for the prescribed drugs sector to remain throughout the European regulatory system.

British lawmakers have additionally known as for an settlement that enables the nation to have continued participation within the European medicines regulatory framework, nevertheless it stays unclear how it will play out within the broader EU negotiations.

The European Medicines Agency has warned drugmakers they needed to be ready for a possible hard Brexit in 2019. It has also expressed “serious concerns” over the availability of some 108 medicines that are manufactured exclusively in the UK.




Read more


Read more

Media Center

Read more